Abstracts tagged "Adipokines and osteoarthritis"

Abstract Number: 2347 • 2016 ACR/ARHP Annual Meeting
Serum Levels of Resistin Are Associated with Synovial Inflammation and Knee Structural Changes in Patients with Symptomatic Knee Osteoarthritis
WEIYU HAN¹, Flavia M Cicuttini², Graeme Jones³ and Changhai Ding³, ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Australia, ³Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: Due to these sparse and inconsistent clinical data, our current study aims to describe the associations between serum levels of resistin, knee synovial inflammation…
Abstract Number: 2397 • 2015 ACR/ARHP Annual Meeting
Detection of Changes in the Serum and Synovial Fluid Levels of Resistin during Flare Ups and Remissions in Primary Knee Osteoarthritis
Hassan Bassiouni, Rheumatology, Al-Azhar University, Cairo, Egypt
Background/Purpose: Resistin is a secreted factor that is elevated following traumatic joint injury, causing matrix degradation and it releases inflammatory cytokines from articular cartilage in…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.